KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination.

doi:10.1186/s12964-024-01667-x

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination.

Cell communication and signaling : CCS - 12 Jun 2024

Rosell Rafael, Jantus-Lewintre Eloisa, Cao Peng, Cai Xueting, Xing Baojuan, Ito Masaoki, Gomez-Vazquez Jose Luis, Marco-Jordán Mireia, Calabuig-Fariñas Silvia, Cardona Andrés Felipe, Codony-Servat Jordi, Gonzalez Jessica, València-Clua Kevin, Aguilar Andrés, Pedraz-Valdunciel Carlos, Dantes Zahra, Jain Anisha, Chandan S, Molina-Vila Miguel Angel, Arrieta Oscar, Ferrero Macarena, Camps Carlos, González-Cao Maria

Abstract excerpt

BACKGROUND: KRAS-mutant non-small cell lung cancer (NSCLC) shows a relatively low response rate to chemotherapy, immunotherapy and KRAS-G12C selective inhibitors, leading to short median progression-free survival, and overall survival. The MET receptor tyrosine kinase (c-MET), the cognate receptor of hepatocyte growth factor (HGF), was reported to be overexpressed in KRAS-mutant lung cancer cells leading to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Omeprazole

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Piperidines

Share to Proto-Oncogene Proteins c-met

Share to Pyridazines

Share to Pyridines

Share to Pyridones

Share to Pyrimidinones

Share to Triazines

Source

Open in PubMed Open full text

Identifiers

PMID: 38867255
DOI: 10.1186/s12964-024-01667-x
PMCID: PMC11167791

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination.PMID 38867255Read ↗

MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review.Semantic proximity Read ↗

Met inhibitors in the treatment of lung cancer: the evidence to date.Semantic proximity Read ↗

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.Semantic proximity Read ↗

[Progress on Mechanism of MET Gene Mutation and Targeted Drugs in Non-small Cell Lung Cancer].Semantic proximity Read ↗

Combination therapy of sotorasib and docetaxel overcomes resistance to sotorasib alone in KRAS G12C mutant lung adenocarcinoma.Semantic proximity Read ↗

Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC.Semantic proximity Read ↗

Efficacy and safety of tepotinib in MET‑altered non‑small cell lung cancer: a meta-analysis.Semantic proximity Read ↗

[Mechanism of c-MET in Non-small Cell Lung Cancer and Its Treatment and Testing].Semantic proximity Read ↗

Tepotinib Improves Prognosis in an Elderly Patient with Poor Performance Status and MET Exon 14 Skipping Mutation-positive Non-small Cell Lung Cancer.Semantic proximity Read ↗

Clinical characteristics and prognostic outcomes in KRAS-mutant non-small cell lung cancer: A real-world study with or without COPD comorbidity.Semantic proximity Read ↗

mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF.Semantic proximity Read ↗

Tepotinib hydrochloride for the treatment of non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.